Search Results

Plus Therapeutics, Inc. today announced it has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP).

Telix Pharmaceuticals Limited (the “Company” or “Telix”) today announces the launch of its initial public offering in the United States (the “Offering”) of 17,000,000 American Depositary Shares (“ADSs”), each representing one ordinary share in Telix.

Gemina Laboratories Ltd. is pleased to announce that it has qualified for trading on the OTCQB Venture Market in the United States operated by the OTC Markets Group Inc. and the Company’s common shares have commenced trading on the OTCQB under the symbol “GLABF.” The Company’s common shares will continue to trade on the CSE Exchange under the symbol “GLAB” and on the Frankfurt Exchange under the symbol “817".

Telix Pharmaceuticals Limited announces that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its American Depository Shares, representing the Company’s ordinary shares, in the U.S. Telix has applied to list the ADSs on the Nasdaq Global Market under the symbol “TLX”.

Adial Pharmaceuticals, Inc. today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office.

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”) today announced that the United States Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 12,006,305, titled “Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof.”